Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone

Four cycles of chemotherapy are required to assess responses of multiple myeloma (MM) patients. We investigated whether circulating endothelial progenitor cells (cEPCs) could be a biomarker for predicting patient response in the first cycle of chemotherapy with bortezomib and dexamethasone, so patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, L., Du, F., Zhang, H.M., Zhang, W.J., Wang, H.X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2015
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541694/
https://www.ncbi.nlm.nih.gov/pubmed/26108099
http://dx.doi.org/10.1590/1414-431X20154558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541694/
https://www.ncbi.nlm.nih.gov/pubmed/26108099
http://dx.doi.org/10.1590/1414-431X20154558

Ejemplares similares